Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

807
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
807
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

1.3K
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
1.3K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Insights and Prognostic Factors in Frontal Fibrosing Alopecia and Lichen Planopilaris: A Retrospective Cohort Study.

Dermatology (Basel, Switzerland)·2026
Same author

Pregnancy outcomes in patients with biologic-exposed psoriasis: A large cohort study of real-world safety.

Journal of the American Academy of Dermatology·2026
Same author

From Onset to Outcome: A Long-term Retrospective, Single centre Study of Guttate Psoriasis from Israel.

Acta dermato-venereologica·2026
Same author

Efficacy of glucagon-like peptide 1 analogues in psoriasis: A cohort study.

JAAD international·2026
Same author

The MATRIX criteria: an internally validated scoring model for biopsy selection in longitudinal melanonychia.

The British journal of dermatology·2026
Same author

Factors Associated With Treatment Response in Granuloma Annulare.

Photodermatology, photoimmunology & photomedicine·2026

Related Experiment Video

Updated: May 4, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.5K

Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris.

Tal Raviv1, Keren Pevzner2, Aviv Barzilai3

  • 1Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. tal.raviv7@gmail.com.

Acta Dermato-Venereologica
|January 3, 2025
PubMed
Summary
This summary is machine-generated.

Rituximab effectively treats pemphigus vulgaris, but prior treatments like mycophenolate mofetil impact remission. Diabetes and shorter disease duration before rituximab are linked to faster relapse in this autoimmune blistering disease.

More Related Videos

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.1K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K

Related Experiment Videos

Last Updated: May 4, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.5K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.1K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K

Area of Science:

  • Immunology
  • Dermatology
  • Autoimmune Diseases

Background:

  • Pemphigus vulgaris is a severe autoimmune blistering disease.
  • Rituximab is a first-line treatment, but prognostic factors for its efficacy are not well-defined.

Purpose of the Study:

  • To identify prognostic factors influencing rituximab outcomes in pemphigus vulgaris patients.
  • To analyze predictors of remission and time to relapse.

Main Methods:

  • Retrospective analysis of 142 pemphigus vulgaris patients treated with rituximab.
  • Data collected included demographics, comorbidities, disease characteristics, and treatment outcomes.

Main Results:

  • Previous mycophenolate mofetil treatment was associated with lower complete remission rates.
  • Diabetes mellitus and disease duration ≤16 months before rituximab correlated with shorter time to relapse.
  • Prior dapsone therapy was linked to extended time to relapse.

Conclusions:

  • Specific patient characteristics and prior treatments significantly influence rituximab response and relapse time in pemphigus vulgaris.
  • Identifying these factors can help predict outcomes and optimize patient selection for rituximab therapy.